Haematuria (positive dipstick, microscopic or visible haematuria)
BioMG follows French guidelines. Adapt it to the guidelines and the tests available where you practise.
Visible haematuria (red urine)
Laboratory tests
- Urine microscopy and culture
- Serum creatinine with eGFR
- Urine protein:creatinine ratio (spot sample)
- Creatine kinase (CK)if needednon-French guidelineDark urine with a dipstick positive for blood but few red cells: consider myoglobinuria [2].
- FBC (heavy, prolonged or poorly tolerated haematuria)if needednon-French guidelineHeavy haematuria or signs of poor tolerance: FBC is part of the baseline tests for macroscopic haematuria in the emergency department [3].
- INR (on VKA)if needednon-French guidelineOn a vitamin K antagonist: a coagulation disorder is a criterion for hospital admission [3]; overdose alone does not explain the haematuria, the work-up is still necessary [4].
- Total PSA (in men, after information, to look for prostate cancer)if needednon-French guidelineNICE says to consider PSA and digital rectal examination in men with visible haematuria, then a suspected cancer pathway above an age-dependent threshold: more than 2.5 µg/L from 40 to 49 years, 3.5 from 50 to 59, 4.5 from 60 to 69, 6.5 from 70 to 79 [5]. An Australian general practice review proposes it after age 50 [6], and a meta-analysis finds prostate cancer in 5.9% of men investigated for macroscopic haematuria [7]. In France, the INCa document on PSA addresses men without symptoms and does not deal with haematuria [8].
- From age 45, unexplained visible haematuria without urinary tract infection: refer to urology (suspected cancer pathway).
Also consider
- Dipstick positive, few red cells? A positive dipstick with few red cells in the pellet suggests myoglobinuria: see the page "CPK élevées".
Dipstick positive for blood: confirm
Outside menstruation and away from a treated infection
- Urine microscopy and culture (red and white cell counts, casts)
Confirmed microscopic haematuria: tests and referral
Laboratory tests
- Serum creatinine with eGFR
- Urine protein:creatinine ratio (spot sample)
- Urine albumin:creatinine ratio on the same sampleif needednon-French guidelineTo look for associated albuminuria (ACR ≥ 30 mg/mmol with haematuria: nephrology opinion) [17].
- Repeat urine microscopy and culture (persistence)if needednon-French guidelineLow-risk patient: recheck at 6 months according to the AUA; after a negative urological work-up: recheck within the year [4].
Do not order
- Urine cytology and urinary tumour markers in the initial evaluation of microscopic haematuria: to be avoided (10% false positives, rarely contributory after a normal cystoscopy) [4].
- Urinary sediment (0219) prescribed in addition to the urine culture: the NABM does not allow the two procedures to be combined, the urine culture already includes the red cell count [16].
- Dipstick or urinary markers to screen for bladder cancer in a person without symptoms: screening not recommended (low incidence) [11].
Sources (21)
- Barocas DA, Boorjian SA, Alvarez RD, et al. Microhematuria: AUA/SUFU Guideline. J Urol. 2020;204(4):778-786.
- Chavez LO, Leon M, Einav S, Varon J. Beyond muscle destruction: a systematic review of rhabdomyolysis for clinical practice. Crit Care. 2016;20(1):135.
- Hicks D, Li CY. Management of macroscopic haematuria in the emergency department. Emerg Med J. 2007;24(6):385-90.
- Arnold MJ. Microscopic hematuria in adults: updated recommendations from the American Urological Association. Am Fam Physician. 2021;104(6):655-657 (résumé de Barocas DA et al., Microhematuria: AUA/SUFU Guideline, J Urol 2020).
- National Institute for Health and Care Excellence (NICE). Suspected cancer: recognition and referral (NG12). 2015, dernière mise à jour 2026 ; recommandations 1.6.4 à 1.6.6.
- O'Connor E, McVey A, Demkiw S, Lawrentschuk N, Murphy DG. Assessment and management of haematuria in the general practice setting. Aust J Gen Pract. 2021;50(7):467-71.
- Hansen RS, Biørn SH, Birk-Korch JB, Sheikh SP, Poulsen MH, Vinholt PJ. Prevalence of prostate cancer in men with haematuria: a systematic review and meta-analysis. BJU Int. 2023;131(5):530-9.
- Institut national du cancer (INCa), après avis de la HAS. Éléments d'information destinés aux médecins concernant la première prescription du PSA chez l'homme asymptomatique. Mars 2016.
- SPILF, comité des référentiels, avec SFGG, AFU, SFMU, SFM, SFPT, SNFMI et CNGE. Infections urinaires masculines aiguës communautaires de l'adulte (IUMACA) : mise à jour des recommandations. Diaporama du groupe recommandations, 20 juin 2026.
- Haute Autorité de santé. Guide du parcours de soins : maladie rénale chronique de l'adulte (MRC). Juillet 2021, mis à jour en septembre 2023.
- European Association of Urology (EAU). Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and CIS), édition présentée au 41e congrès de l'EAU, Londres, 2026 ; chapitre 5 « Diagnosis » (sections 5.1 à 5.9).
- Nielsen M, Qaseem A ; High Value Care Task Force of the American College of Physicians. Hematuria as a Marker of Occult Urinary Tract Cancer: Advice for High-Value Care From the American College of Physicians. Ann Intern Med. 2016;164(7):488-97.
- Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF). S3-Leitlinie Früherkennung, Diagnose, Therapie und Nachsorge des Harnblasenkarzinoms, Langversion 3.1, juillet 2026.
- Barocas DA, Boorjian SA, Alvarez RD, et al. Microhematuria: AUA/SUFU Guideline. J Urol. 2020;204(4):778-786.
- National Institute for Health and Care Excellence (NICE). Chronic kidney disease: assessment and management (NG203). 2021 ; recommandations 1.1.16 à 1.1.19.
- Assurance maladie. Nomenclature des actes de biologie médicale (NABM), version 105 du 2 juin 2026 : actes 5201 (ECBU) et 0219 (culot urinaire).
- Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024;105(4S):S117-S314 (figure 48).
- Barocas DA, Lotan Y, Matulewicz RS, et al. Updates to Microhematuria: AUA/SUFU Guideline (2025). J Urol. 2025;213(5):547-557.
- Linder BJ, Bass EJ, Mostafid H, Boorjian SA. Guideline of guidelines: asymptomatic microscopic haematuria. BJU Int. 2018;121(2):176-83.
- US Preventive Services Task Force. Bladder Cancer in Adults: Screening. Final Recommendation Statement, 15 août 2011 (grade I ; veille documentaire de juillet 2024).
- UK National Screening Committee. Bladder cancer : recommandation de dépistage, dernière revue de mars 2026.